ADIM
EXEL icon

Alpha DNA Investment Management’s Exelixis EXEL Stock Holding History

Alpha DNA Investment Management’s Portfolio EXEL Stock Details EXEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-14,397
Closed -$479K – 70
2024
Q4 		$479K Buy
+14,397
New +$467K 0.18% 115
2021
Q2 		– Sell
-18
Closed – – 279
2021
Q1 		$0 Hold
18
– – ﹤0.01% 716
2020
Q4 		$0 Buy
+18
New +$377 ﹤0.01% 602

Other funds holding EXEL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Alpha DNA Investment Management's EXEL Position: Q1 2025 in Review

Alpha DNA Investment Management sold out of Exelixis (EXEL) in Q1 2025, closing a stake of 14,397 shares — an estimated $479K sold.

Alpha DNA Investment Management first reported a position in EXEL in Q4 2020 and held it in 3 quarters. The position peaked at $479K in Q4 2024. 557 funds tracked by Wall St. Rank hold EXEL as of Q1 2025.

  • Alpha DNA Investment Management reported no remaining Exelixis position as of Q1 2025 after selling out during the quarter.
  • Alpha DNA Investment Management sold 14,397 Exelixis shares in Q1 2025, an estimated $479K.
  • Alpha DNA Investment Management first reported a position in Exelixis in Q4 2020 and held it in 3 quarters.
  • Alpha DNA Investment Management's Exelixis position peaked at $479K in Q4 2024.
  • 557 funds tracked by Wall St. Rank held Exelixis as of Q1 2025.

Based on Alpha DNA Investment Management's 13F filing for Q1 2025, filed 19 May 2025.